Renal protective strategies in heart transplant patients

Current Opinion in Cardiology

Volumn 22, Issue 2, 2007, Pages 133-138

  Cantarovich, Marcelo ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Calcineurin inhibitor; Heart transplantation; Interleukin 2 receptor monoclonal antibodies; Mycophenolate mofetil; Rapamycin; Renal protection

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; CARDIAC GRAFT REJECTION; CARDIAC PATIENT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART GRAFT; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCINEURIN; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC;

EID: 33846871197     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32801466e4     Document Type: Review

References (42)

1. Shiba N, Chan MCY, Kwok BWK, et al. Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience. J Heart Lung Transplant 2004; 23:155-164.
2. Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression. Transplantation 1997; 65:664-668.
3. Zietse R, Balk AH, van den Dorpel MA, et al. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994; 14:1-5.
4. Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients - a seven-year follow-up. Transplantation 1990; 50:589-593.
5. Anguita M, Arizon JM, Valles F, et al. Influence on survival after heart transplantation of contraindications seen in transplant recipients. J Heart Lung Transplant 1992; 11:708-715.
6. Alam A, Badovinic K, Ivis F, et al. Increased mortality in heart transplant patients with end-stage renal disease requiring chronic dialysis: the Canadian experience. Am J Transplant 2007; 7:461-465.
7. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
8. El Kossi MMH, Ibrahim A, Lock TJ, El Nahas AM. Impact of cardiac transplantation on kidney function: a single-center experience. Transplant Proc 2003; 35:1527-1531.
9. Cantarovich M, Giannetti N, Edwardes MD, et al. Early drop of creatinine clearance is a strong predictor of long-term renal dysfunction, chronic dialysis and mortality after heart transplantation [abstract]. Am J Transplant 2005; 5 (Suppl 11):168.
10. Lindelow B, Bergh C-H, Herlitz H. Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 2000; 11:951-957.
11. Veillon S, Caillard S, Epailly E, et al. Chronic renal failure after cardiac transplantation: predictive factors and influence on mortality - results of a monocenter study in 141 patients. Transplant Proc 2002; 34:2819-2820.
12. Rubel JR, Milford EL, McKay DB, Jarcho JA. Renal insufficiency and end-stage renal disease in the heart transplant population. J Heart Lung Transplant 2004; 23:289-300.
13. Esposito C, Semeraro L, Bellotti N, et al. Risk factors for chronic renal dysfunction in cardiac allograft recipients. Nephron 2000; 84:21-28.
14. Senechal M, Dorent R, Tezenas du Montcel S, et al. End-stage renal failure and cardiac mortality after heart transplantation. Clin Transplant 2004; 18:1-6.
15. Satchithananda DK, Parameshwar J, Sharples L, et al. The incidence of end-stage renal failure in 17 years of heart transplantation: a single center experience. J Heart Lung Transplant 2002; 21:651-657.
16. Cantarovich M, Besner JG, Barkun JS, et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12:243-249.
17. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68:1356-1361.
18. Sindhi R, LaVia MF, Paulling E, et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen. Transplantation 2000; 69:432-436.
19. Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr postdose levels compared with trough levels in stable heart transplant patients. Transplantation 1999; 68:1839-1842.
20. Delgado DH, Rao V, Hamel J, et al. Monitoring of cyclosporine 2-h postdose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant 2005; 24:1343-1346.
21. Caforio AL, Tona F, Piaserico A, et al. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transplant Int 2005; 18:116-124.
22. Cantarovich M, Giannetti N, Cecere R. Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving antithymocyte globulin induction. Clin Transplant 2003; 17:144-150.
23. Cantarovich M, Ross H, Arizon JM, et al. A 12-month, multicenter, randomized adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month results. Am J Transplant 2005; 5 (Suppl 11):249.
24. Billingham M, Cary N, Hammond M, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant 1990; 9:587-593.
25. 0 values for monitoring cyclosporine therapy in stable heart transplant recipients. Transplant Proc 2005; 37:1355-1359.
26. Regazzi MB, Rinaldi M, Molinaro M, et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Ther Drug Monit 1999; 21:2-7.
27. Armendariz Y, Pou L, Cantarell C, et al. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 2005; 27:431-434.
28. Aumente Rubio MD, Arizon del Prado JM, Lopez Malo de Molina MD, et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. Transplant Proc 2003; 35:1988-1991.
29. Mardigyan V, Gianetti N, Cecere R, et al. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant 2005; 24:1614-1618.
30. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377-1386.
31. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25:434-439.
32. Dureau G, Obadia JF, Chuzel M, Boissonnat P. Introduction of mycophenolate mofetil and cyclosporine withdrawal in heart transplant patients with progressive deteriorating renal function. Transplant Proc 2000; 32:461-462.
33. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20:2517-2523.
34. Watson CJE, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5:2496-2503. In this manuscript the authors reported a significant improvement in the glomerular filtration rate in renal transplant patients converted from CNI to rapamycin.
35. Bestetti R, Theodoropoulos TA, Burdmann EA, et al. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation 2006; 81:692-696. In this manuscript the authors reported a significant improvement in renal function in heart transplant patients converted from CNI to rapamycin.
36. Groetzner J, Kaczmarek I, Landwehr P, et al. Renal recovery after conversion to a calcineurin-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004; 25:333-341.
37. Potter BJ, Giannetti N, Edwardes MD, et al. Calcineurin inhibitor substitution with sirolimus versus reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients. Clin Transplant 2007 (in press).
38. Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338:161-165.
39. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 210 International Study Group. Lancet 1997; 350:1193-1198.
40. Cantarovich M, Metrakos P, Giannetti N, et al. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor 'holiday' in solid organ transplant patients with acute renal dysfunction. Transplantation 2002; 73:1169-1172.
41. Cantarovich M, Giannetti N, Routy J-P, Cecere R. Calcineurin inhibitor substitution ('retirement') with anti-CD25 monoclonal antibodies: a novel strategy in long-term heart transplant patients with progressive renal dysfunction. Transplantation 2006; 82 (Suppl 3):552-553.
42. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 2005; 67:799-812.